Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T09:05:22.275Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevention of Premature Mortality Among Patients with Schizophrenia: The Need for Primary Prevention Efforts in Cardiovascular Disease

Published online by Cambridge University Press:  07 November 2014

Charles H. Hennekens
Get access Rights & Permissions [Opens in a new window]

Extract

Patients with schizophrenia have a markedly reduced lifespan compared with the general population. In the United States today, patients with schizophrenia have an average life expectancy of ∼61 years, about 20% lower than that of the general population, in which life expectancy is ∼76 years.

Type
Clinical Information Supplement
Information
CNS Spectrums , Volume 13 , supplement S10: Elevating the Standard of Care in the Management of Cardiometabolic Risk Factors in Patients with Mental Illness , June 2008 , pp. 9 - 10
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Hennekens, CH, Hennekens, AR, Hollar, D, Casey, DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–1121.CrossRefGoogle ScholarPubMed
2. Heart Disease and Stroke Statistics - 2006 Update. American Heart Association. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3036355. Accessed November 15, 2007.Google Scholar
3. Grundy, SM, Balady, GJ, Criqui, MH, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation. 1998;97(18):1876–1887.CrossRefGoogle ScholarPubMed
4. Grundy, SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol. 2002;90(8A):11i–21i.CrossRefGoogle ScholarPubMed
5. Chen, Z, Boreham, J. Smoking and cardiovascular disease. Semin Vasc Med. 2002;2(3):243–252.Google Scholar
6. Peto, R, Darby, S, Deo, H, Silcocks, P, Whitley, E, Doll, R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321(7257):323–329.CrossRefGoogle ScholarPubMed
7. Ford, ES, Giles, WH, Dietz, WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359.Google Scholar
8. National Health and Nutrition Examination Survey. Anthropometric Reference Data, United States, 1988–1994. National Center for Health Statistics. Available at: http://www.cdc.gov/nchs/about/major/nhanes/Anthropometric%20Measures.htm. Accessed May 22, 2008.Google Scholar
9. Grundy, SM, Cleeman, JI, Merz, CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.CrossRefGoogle ScholarPubMed
10. Fonarow, GC, Watson, KE. Effective strategies for long-term statin use. Am J Cardiol. 2003;92(1A):27i–34i.CrossRefGoogle ScholarPubMed
11. Pearson, TA, Laurora, I, Chu, H, Kafonek, S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459–467.CrossRefGoogle ScholarPubMed
12. Hebert, PR, Gaziano, JM, Chan, KS, Hennekens, CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278(4):313–321.CrossRefGoogle ScholarPubMed
13. Baigent, C, Keech, A, Kearney, PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.Google ScholarPubMed
14. Sheridan, S, Pignone, M, Donahue, K. Screening for high blood pressure: a review of the evidence for the U.S. Preventive Services Task Force. Am J Prev Med. 2003;25(2):151–158.CrossRefGoogle ScholarPubMed
15. Hennekens, CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97(11):1095–1102.Google Scholar
16. Manson, JE, Nathan, DM, Krolewski, AS, Stampfer, MJ, Willett, WC, Hennekens, CH. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA. 1992;268(1):63–67.CrossRefGoogle ScholarPubMed
17. Manson, JE, Hu, FB, Rich-Edwards, JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med. 1999;341(9):650–658.Google Scholar
18. Hennekens, CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry. 2007;68(suppl 4):4–7 CrossRefGoogle ScholarPubMed
19. World Health Organization. Cardiovascular disease: prevention and control. World Health Organization Web site. Available at: http://who.int/dietphysicalactivity/publications/facts/cvd/en. Accessed May 22, 2008.Google Scholar
20. Meltzer H Y, Alphs, L, Green, AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.Google Scholar
21. Osby, U, Correia, N, Brandt, L, Ekbom, A, Sparen, P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1–2):21–28.CrossRefGoogle ScholarPubMed